Research at Oslo University Hospital

The Norwegian Cancer Society awards the King Olav V Cancer Research Prize each year to a researcher who has particularly promoted the quality of Norwegian cancer research. The prize was first awarded in 1992 and Karl-Johan Malmberg is the 34th winner of the prize, which amounts to one million NOK. He has been honoured with the prestigious prize for his groundbreaking work on how the body's own cells can detect and eliminate cancer. Malmberg is professor at the University of Oslo and head of the Natural Killer Cell Biology and Cell Therapy research group at the Institute for Cancer Research at Oslo University Hospital.

The Institute for Cancer Research at Oslo University Hospital's Annual Report for 2024 is now available online and celebrates the institute's 70th Anniversary (founded in 1954). Alongside key figures and display of our outstanding research, we report on recruitment, training and career development, translation and innovation, dissemination, public outreach, and collaboration in Norway and abroad.

ICR groups are key partners in over 20 clinical trials and leaders in more than 120 translation and innovation projects, many of which involve collaborative efforts with industry partners. Our 370 employees in six research departments, 26 research groups, 29 project groups, and seven core facility units represent a vibrant environment and a fully-fledged cancer research organisation. Our staff's engagement in scientific and public discourse through talks, meetings, events, and media appearances underscores our proactive approach to knowledge dissemination and societal impact.

Read more in the Annual report here: Single page format - Double page format

Annual reports 2014 - 2024

The Norwegian Health Association (Nasjonalforeningen for folkehelsen) distributes the Heart Research Award each year as a recognition and reward to a researcher who has shown significant results in cardiovascular research.
This year's award went to Sigrun Halvorsen, who is head of the Department of Cardiology at Oslo University Hospital and professor at the University of Oslo.
Halvorsen received the award for her many years of contribution to better treatment and new guidelines within the cardiovascular field, both in Norway and internationally, her strong expertise in research communication and ability to translate her research results into clinical patient treatment.

Mitochondria are essential for cellular energy production and homeostasis, and their selective degradation through mitophagy is critical for maintaining cell function. However, the molecular mechanisms governing this process remain incompletely understood.

Now, Laura Trachsel-Moncho and co-workers in Anne Simonsen’s group identify the endosomal protein SNX10 as a modulator of piecemeal mitophagy, a process involving the selective degradation of mitochondrial components. They show that SNX10 localizes to early endosomes in normal conditions but associates with mitochondria-containing endosomal structures under hypoxia-mimicking stress. Loss of SNX10 leads to increased turnover of specific mitochondrial proteins, reduced mitochondrial respiration, and elevated reactive oxygen species (ROS) levels. Furthermore, zebrafish larvae lacking Snx10 exhibit reduced COX-IV levels and increased oxidative stress and cell death, demonstrating the physiological relevance of Snx10 in mitochondrial homeostasis.

These findings uncover an unexpected role for SNX10 in mitochondrial quality control and highlight its importance in cellular adaptation to metabolic stress.

Mev Dominquez-Valentin from the Department of Tumor Biology at the Institute for Cancer Research is senior author on a study recently published in the prestigious journal Clinical Gastroenterology and Hepatology, entitled: "Characterization of Screening Strategies for Lynch Syndrome in Latin America.” The study involves the collaborations of more than 50 investigators from 24 representative genetic cancer registries/center of 8 countries from Latin America, highlighting the significant insights we've gained into Lynch Syndrome (LS) screening methods across the region. The results emphasize challenges in hereditary cancer syndrome screening in Latin America and the need for enhanced strategies. Other OUS researchers involved in the study are Eivind Hovig, Pål Møller and Vessela Kristensen.

Oslo University Hospital was introduced as a new partner of the EUCAIM consortium at a meeting in Brussels on February 6th where the European Commission, together with the European Society of Radiology (ESR), and EUCAIM brought together 160 leading experts to explore how the European Cancer Imaging Initiative harnesses health data and Artificial Intelligence to advance cancer detection and treatment.  
The OUH activities in EUCAIM will be co-organized by research group leaders Kyrre E. Emblem (MRI Research & Technology) and Atle Bjørnerud (Computational Radiology & Artificial Intelligence), at the department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine.

The European doctoral network Mac4Me (Macrophage Targets for Metastatic Treatment) is a 48-month project that addresses both technical and social challenges in cancer metastasis, focusing on three tumour types that show poor response to current immunotherapies: neuroblastoma, breast, and prostate cancer. Mac4Me is a Horizon Europe MSCA (Marie Sklodowska-Curie Actions) Doctoral Network. The network will train 18 Doctoral Candidates to study the tumour microenvironment at metastatic sites. The project is led by a consortium of 14 partners, that includes Oslo University Hospital.
Tero Aittokallio, leader of the Computational Systems Medicine research group at the Institute for Cancer Research, is one of the supervisors, who were selected for their exceptional academic qualifications. The doctoral researcher at OUS will apply multi-modal AI algorithms to define new targets for improved immunotherapy.